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Abstract
Background: Gastro-esophageal reflux disease (GERD) is a common disease. It impairs health related
quality of life (HRQL). However, the impact on utility scores and work productivity in patients with
moderate to severe GERD is not well known.
Methods: We analyzed data from 217 patients with moderate to severe GERD (mean age 50, SD 13.7)
across 17 Canadian centers. Patients completed three utility instruments – the standard gamble (SG), the
feeling thermometer (FT), and the Health Utilities Index 3 (HUI 3) – and several HRQL instruments,
including Quality of Life in Reflux and Dyspepsia (QOLRAD) and the Medical Outcomes Short Form-36
(SF-36). All patients received a proton pump inhibitor, esomeprazole 40 mg daily, for four to six weeks.
Results: The mean scores on a scale from 0 (dead) to 1 (full health) obtained for the FT, SG, and HUI 3
were 0.67 (95% CI, 0.64 to 0.70), 0.76 (95% CI, 0.75 to 0.80), and 0.80 (95% CI, 0.77 to 0.82) respectively.
The mean scores on the SF-36 were lower than the previously reported Canadian and US general
population mean scores and work productivity was impaired.
Conclusion: GERD has significant impact on utility scores, HRQL, and work productivity in patients with
moderate to severe disease. Furthermore, the FT and HUI 3 provide more valid measurements of HRQL
in GERD than the SG. After treatment with esomeprazole, patients showed improved HRQL.
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Background
The global prevalence of gastro-esophageal reflux disease
(GERD), defined as heartburn once daily, is estimated to
range from 5 to 7% but varies widely and depends on the
definition used [1]. For example, 25% of the adult popu-
lation in Belgium [2], nearly 18% in Australia [3], 20% in
the United States and 9 % in Canada reported GERD
symptoms once a week or more [4,5]. While heartburn is
the leading symptom in GERD, the disease is associated
with a broad range of esophageal problems, including
acid regurgitation, epigastric pain, esophageal erosions
and complications such as Barrett's esophagus, esopha-
geal adenocarcinoma and esophageal stricture. GERD is
also associated with a variety of extra-esophageal prob-
lems, including sleep disturbances, noncardiac chest pain,
asthma, chronic cough and hoarseness [6].
Clinicians and health services researchers are becoming
more aware of the importance of patient-reported out-
comes (PROs), including health related quality of life
(HRQL) in understanding the burden of disease and the
outcome of medical treatment. While physiologic meas-
ures provide information to clinicians, these outcomes are
often not important to patients [7] and they correlate
poorly with functional status or well-being, the areas in
which patients are mostly interested. For example, the
majority of patients with typical symptoms of GERD do
not have endoscopic evidence of esophagitis [8]. PROs
assist in providing a better understanding of treatment
outcomes from the patient's perspective by translating
clinical improvement into patient-important outcomes.
Moreover, HRQL assessment is important for measuring
quality of care, clinical effectiveness, and in reimburse-
ment decisions [9,10].
The use of validated questionnaires is appropriate for
measuring PROs in clinical trials [11,12]. There are two
categories of HRQL measures; disease-specific and generic
HRQL instruments [13,14]. Disease-specific instruments
are used to describe the burden of disease and treatment
outcomes in patients with a specific disease, and generic
instruments measure the overall HRQL of patients,
including physical, emotional, and social function, as well
as their level of general performance at work and in daily
life across different diseases [15].
Utility measures, one type of generic health status meas-
ures, are based on economic and decision theory [16].
These instruments measure patient preferences and gener-
ate preference or utility scores for respondents' health
states on a 0 to 1.0 scale where 0 typically equals dead and
1.0 is full health [17]. In this manuscript we will use the
term "utility" for all scores generated with preference
based instruments although. The standard gamble (SG) is
regarded as the reference standard for utility measurement
[18-20]. Another utility instrument is the feeling ther-
mometer (FT), a visual analogue scale presented in the
form of a thermometer [18]. When completing this instru-
ment, patients choose the score on the thermometer that
represents the value they place on their health state. It is
far simpler than the SG and has shown good responsive-
ness and validity in several studies [21-24]. The health
utility index 3 (HUI 3) is a multi attribute utility instru-
ment designed to classify a patient's health status based
on rating of a set of defined items [25,26].
The aim of this analysis was to address the impact of
GERD on utility scores, HRQL and work productivity in
patients with moderate to severe GERD and to evaluate
the construct validity of utility instruments as measures of
HRQL.
Methods
Patients
We enrolled 249 uninvestigated outpatients with a clini-
cal diagnosis of moderate to severe GERD in 13 specialty
centers and 4 general practices across Canada between
March 2002 and March 2003. Table 1 lists the definitions
of symptoms severity. To evaluate the aims described in
the introduction of this manuscript, we utilized data from
a study that had as primary aim the comparison of two
different formats of administering the SG and the FT [27].
Therefore, the current publication describes the data from
the baseline visit of the 217 patients (87%) who com-
pleted the study and the responsiveness of the QOLRAD
and the four symptoms questionnaire after four to six
weeks of treatment with a proton pump inhibitor (PPI),
esomeprazole. The main inclusion criteria were a clinical
diagnosis of GERD, main symptom of heartburn, age
greater 18 years, symptomatic for three months or longer,
and off PPI for the 2 weeks prior to questionnaire admin-
istration. GERD was defined as a burning feeling, rising
from the stomach or lower part of the chest up towards
the neck. We describe the detailed eligibility criteria else-
where [27].
Table 1: Definition of symptom severity
Moderate problem: Cannot be ignored but does not influence my daily life.
Moderately severe problem: Cannot be ignored and occasionally limits my daily activities.
Severe problem: Cannot be ignored and often limits my concentration on daily activities.
Very severe problem: Cannot be ignored and markedly limits my daily activities and often requires rest.BMC Gastroenterology 2005, 5:23 http://www.biomedcentral.com/1471-230X/5/23
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Study design
Patients completed several utility and HRQL instruments
during a clinic visit and provided demographic and clini-
cal data. The visit lasted approximately 80 minutes. An
experienced research coordinator from the method center
trained all site interviewers in a daylong session in HRQL
instrument administration. Ethic review boards at all
study sites approved the study protocol and all patients
signed an informed consent form prior to enrollment in
the study.
Utility measures
The feeling thermometer (FT) is a visual analogue scale
shown as a thermometer in which the best state is full
health (equal to a score of 100) and the worst state is dead
(a score of 0) [18]. It has shown good responsiveness and
validity in several studies [21-24]. In this trial, we used a
self-administered form of the FT [27,28].
The SG [18-20] offers patients two options from which a
choice must be made: Choice A is the certain outcome
that the patient will stay in a health state (their own health
state, or a marker state) for t years until death. We varied t
depending on the patient's age as follows: patients aged
more than 80 years, t = the rest of the patient's lifetime;
age 76 – 80 years, t = 10 years; age 66 – 75 years, t = 15
years; age 56 – 65, t = 25 years; age 46 – 55 years, t = 30
years; age 36 – 45 years, t = 35 years; age 26 – 35 years, t =
40 years; age 18 – 25 years, t = 45 years. Specifying the
duration of remaining life means that patients use the
same time frame as other patients of the same age, and
reduces the random error that might result from patients
inferring different time frames. Varying time frame by age
minimizes an additional lack of realism that could arise if
one chose a single time frame and either young patients
have an unrealistically short duration of remaining life, or
old patients have an unrealistically long duration. The
alternative (choice B) is a hypothetical treatment with 2
outcomes: 1) returning to full health (probability p) for t
years, at the end of which the patient dies or 2) immediate
death (probability 1-p). Interviewers used a chance board
with a ping-pong approach varying the probability p in
steps of 0.05 to obtain the value, p*, where the patient
considered choice A equal to choice B. This indifference
probability, p*, is the utility value for the patient's own
health in choice A in the interval from dead (= 0) to full
health (= 1). The greater the respondent's willingness to
accept the risk of a worse outcome (e.g dead) to avoid the
health state in choice A, then the lower is the utility of the
state in choice A to them.
The HUI 3 is a 15 item self-administered questionnaire. It
has 8 attributes that include vision, hearing, speech,
ambulation, dexterity, emotion, cognition and pain. We
calculated a utility score on a 0 to 1.0 scale where 0 repre-
sents dead and 1.0 represents full health [26]. HUI has
been shown to be a reliable, responsive and valid measure
in a wide variety of clinical studies [25].
In addition we used the four symptoms questionnaire that
comprises a series of four questions on which patients rate
how they felt for the past week using a seven-point Likert
scale ranging from no problem to very severe problem.
The four symptoms questionnaire evaluates heartburn,
acid reflux, belching, and stomach ache.
Disease-specific HRQL
The quality of life in reflux and dyspepsia (QOLRAD) con-
sists of 25 items across five dimensions: emotional dis-
tress, sleep dysfunction, vitality, food/drink problems,
and physical/social functioning. Patients provide answers
on a seven-point Likert-type scale. The lower the value, the
more severe is the impact on daily functioning. The QOL-
RAD is reliable, valid and responsive [29-31].
GERD-specific work productivity and activity impairment 
questionnaire
The GERD-specific Work Productivity and Activity Impair-
ment questionnaire (WPAI-GERD) contains 8 items
(Table 2) that uses a one-week recall period and measures
absence from work, reduced productivity while at work
and reduced productivity while doing regular daily activi-
ties other than work [32].
Table 2: GERD-specific work productivity and activity impairment questionnaire (WPAI-GERD)
1. Are you currently employed?
2. During the past 7 days, how many days did you work?
3. How many of those days did you have reflux symptoms while working?
4. During the past 7 days, how many hours were you absent from work because of problems associated with your reflux symptoms?
5. During the past 7 days, how many hours were you absent from work for any other reason than problems associated with your reflux symptoms?
6. During the past 7 days, how many hours did you actually work?
7. During the past 7 days, how much did your reflux symptoms on average affect your normal productivity while you were working?
8. During the past 7 days, how much did your reflux symptoms on average affect your normal productivity while you were doing your regular 
activities, other than working?BMC Gastroenterology 2005, 5:23 http://www.biomedcentral.com/1471-230X/5/23
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Health profile measure
The Medical Outcomes Study Short Form-36 (SF-36) is a
generic instrument that assesses a wide range of health
problems, including GERD [34]. It consists of 8 domains
including physical functioning, role limitations-physical,
bodily pain, general health, vitality, social functioning,
role limitations-emotional, and mental health. The SF-36
scores range from 0 to 100, with higher scores indicating
better functioning and well-being.
HRQL and utilities for other health states
We compared the SF-36 scores for the Canadian general
population reported by Hopman et al. [33], and the US
general population, depression, hypertension, diabetes
extracted from the Medical Outcome Study and reported
by Revicki et al. [34-37] to the SF-36 scores of our study
patients. In addition, we compared the utility scores of
patients enrolled in this study with those of other patients
reported previously, as utility ratings are comparable
across conditions because they provide scores between 0
(dead) and 1 (full health) that are not disease specific
[38,39]. A priori, we determined that we would focus on
patients with common diseases for whom utility assess-
ments are available.
Statistical analysis
We report baseline instrument scores as means with 95%
confidence intervals (CI). The QOLRAD and the four
symptoms questionnaire responsiveness to treatment are
shown as mean change scores with 95% CI. We also eval-
uated the cross-sectional construct validity of the utility
instruments by calculating Pearson's correlation coeffi-
cients of the scores on the FT, SG and HUI 3 with the val-
idation instruments the QOLRAD, the SF-36, and the four
symptoms questionnaire. We assumed that higher corre-
lations with the validation instruments would indicate
greater construct validity. For interpretation of the correla-
tions we considered correlations of less than 0.2 as very
weak, from 0.2 to 0.35 as weak, from 0.35 to 0.5 as mod-
erate and of more than 0.5 as strong. We compared mean
physical and mental component summary scores on the
SF-36 of our study population and the previously reported
scores of the Canadian population, the US population,
clinical depression, diabetes, and hypertension using Stu-
dent's t tests [33-37].
Results
Baseline characteristics and burden of disease
Table 3 shows the baseline characteristics of the patients.
The mean age was 50 years (range 20 to 82), 53% were
females, 69%% were employed, and the mean number of
months since diagnosis was 86 (range 1 to 504). Table 4
presents mean QOLRAD scores and the mean scores for
the four symptoms questionnaire along with the mean
scores change after 4 weeks of PPI treatment. GERD has
the greatest impact on the vitality and food/drink
domains of the QOLRAD (scores of 4.3 and 3.8 respec-
tively). The most severe symptoms were heartburn and
acid reflux with scores of 4.5 and 4.1 respectively. PPI
treatment significantly improved the scores of the QOL-
RAD and the four symptoms.
Table 3: Baseline characteristics of patients with moderate or 
severe GERD mean age 50 years, range 20 to 82
Frequency (Percentage) (N 217)
Female 114 (52.5)
Single 33 (15.2)
Lives alone 23 (10.6)
Employed 153 (71.0)
Never smoked 94 (43.5)
Ever smoked 122 (56.5)
Caucasian 191 (88.0)
Other ethnic groups 26 (12.0)
Moderate GERD* 112 (51.6)
Moderately severe GERD* 74 (34.1)
Severe GERD* 27 (12.5)
Very severe GERD* 4 (1.8)
*GERD: Gastroesophageal reflux disease
Table 4: QOLRAD and four symptoms questionnaire baseline scores and mean change scores after 4 week treatment with PPI
Instrument Mean baseline score (95% CI) Mean change score (95% CI)
QOLRAD emotional Distress 4.5 (4.3, 4.7) (N = 217) 2.0 (1.9, 2.2) (N = 217)
QOLRAD sleep Disturbance 4.5 (4.3, 4.7) (N = 217) 2.1 (1.9, 2.3) (N = 217)
QOLRAD food/drink problems 3.8 (3.7, 4.0) (N = 217) 2.5 (2.3, 2.6) (N = 217)
QOLRAD physical/social 5.5 (5.3, 5.6) (N = 217) 1.3 (1.1, 1.4) (N = 217)
QOLRAD vitality 4.3 (4.1, 4.5) (N = 217) 2.1 (1.9, 2.3) (N = 217)
Stomach pain 3.9 (3.7, 4.1) (N = 217) -1.9 (-2.2, -1.7) (N = 217)
Heartburn 4.5 (4.3, 4.7) (N = 217) -2.9 (-3.1, -2.7) (N = 216)
Belching 3.6 (3.4, 3.8) (N = 216) -1.6 (-1.8, -1.4) (N = 216)
Acid reflux 4.1 (3.9, 4.3) (N = 215) -2.4 (-2.6, -2.2) (N = 212)
QOLRAD: Quality of life in reflux and dyspepsia, PPI: Proton pump inhibitorBMC Gastroenterology 2005, 5:23 http://www.biomedcentral.com/1471-230X/5/23
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WPAI-GERD
A total of 153 (71%) patients were employed. The per-
centage of overall work impairment secondary to GERD
that included absence from work plus time lost due to
reduced productivity was 16% (95% CI, 12.9 to 18.8),
which corresponds to 6.7 hours lost per week due to
GERD symptoms. Furthermore, the reduced productivity
during activities other than work in 216 patients was 21%
(95% CI, 18.0 to 24.0).
Construct validity of the utility instruments
The correlations of the FT and HUI 3 with the QOLRAD
and SF-36 domains were moderate. However, the SG
showed lower correlations than the FT and the HUI 3. The
FT had the highest, albeit weak correlation with the four
symptoms questionnaire (Table 5).
Comparison of utility scores with other diseases
The systematic review by Morimoto et al. of utility meas-
ures reported SG weighted means for asthma, chronic
renal failure, and angina pectoris of 0.88 (range 0.82–
0.91), 0.52 (range 0.49–0.55), and 0.76 (range 0.64–
0.97), respectively [38]. The systematic review by Post et
al. revealed time trade off (TTO) and SG in survivors of
minor stroke to be 0.72 (range 0.71–0.81), and 0.89
(range 0.81–0.95) respectively [39]. We previously
reported baseline scores for the FT and SG in patients with
moderate to severe COPD to be 0.60 (SD 0.18), and 0.66
(SD 0.27) respectively [24]. In this study, the utilities
obtained for the FT, SG, and HUI 3 were 0.67 (95% CI,
0.64–0.70), 0.78 (95% CI, 0.75–0.80), and 0.80 (95% CI,
0.77–0.82) respectively.
Comparison of the SF-36 scores to other diseases and the 
general population
The mean scores on the SF-36 range from 42.8 to 47.7
across the different SF-36 domains (Table 6). These scores
are significantly lower than the Canadian and US general
population mean scores on the physical and mental com-
ponent summaries (table 7) [33,35]. Table 7 also demon-
strates the comparison of the SF-36 scores of our patients
to other groups of patients included in the Medical Out-
comes Study and reported by Revicki et al. [35,36,40].
Discussion
We determined the impact of GERD on utility scores,
HRQL and work productivity in patients with moderate to
severe GERD and the cross-sectional construct validity of
three utility instruments (FT, SG, and HUI 3). Although
the comparisons we made are indirect, the results of this
study indicate that GERD causes important reductions in
HRQL and utility when compared to the Canadian and
US general population and to those of patients with a
Table 5: Correlation of the FT, SG and HUI 3 with the validation instruments (P-values)
Instrument FT SG HUI 3
SF-36 PCS (N = 212) 0.40 (<0.001) 0.31 (<0.001) 0.46 (<0.001)
SF-36 MCS (N = 212) 0.34 (<0.001) 0.22 (<0.001) 0.54 (<0.001)
QOLRAD emotional Distress 0.48 (<0.001) 0.27 (<0.001) 0.38 (<0.001)
QOLRAD sleep disturbance 0.39 (<0.001) 0.25 (<0.001) 0.23 (<0.001)
QOLRAD food/drink problem 0.37 (<0.001) 0.28 (<0.001) 0.25 (<0.001)
QOLRAD physical/social 0.38 (<0.001) 0.26 (<0.001) 0.41 (<0.001)
QOLRAD vitality 0.48 (<0.001) 0.30 (<0.001) 0.44 (<0.001)
Stomach pain 0.32 (<0.001) 0.15 (0.032) 0.26 (<0.001)
Heartburn 0.32 (<0.001) 0.13 (0.059) 0.09 (0.174)
Belching (N = 216) 0.20 (0.003) -0.09 (0.193) 0.09 (0.189)
Acid reflux (N = 215) 0.34 (<0.001) 0.15 (0.015) 0.14 (0.046)
FT: Feeling thermometer; SG: Standard gamble; HUI 3: Health utility index 3; SF-36: Short form 36; PCS: Physical component summary; MCS: 
Mental component summary; QOLRAD: Quality of life in reflux and dyspepsia. N = 217 unless indicated otherwise.
Table 6: SF-36 mean scores
Instrument Mean 95% CI
SF-36 physical functioning 46.6 (N = 213) 45.4, 47.8
SF-36 physical-Role 45.5 (N = 216) 44.0, 47.0
SF-36 bodily pain 42.8 (N = 217) 41.6, 44.1
SF-36 general health 46.2 (N = 216) 44.9, 47.5
SF-36 vitality 45.9 (N = 217) 44.6, 47.3
SF-36 social functioning 47.7 (N = 217) 46.3, 49.1
SF-36 role emotional 46.5 (N = 216) 44.9, 48.1
SF-36 mental health 46.9 (N = 217) 45.5, 48.3
SF-36: Short form 36BMC Gastroenterology 2005, 5:23 http://www.biomedcentral.com/1471-230X/5/23
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range of other chronic conditions. Heartburn and acid
reflux were reported by our patients to have the worst
impact on symptoms using the four symptoms question-
naire. The QOLRAD as well as the symptom scores
improved after esomeprazole treatment although this
study did not include a placebo group. In addition, our
data indicate that GERD causes a considerable loss in
work productivity.
The strengths of this study include the use of several utility
and HRQL instruments that allow comparison to other
chronic conditions. By using several quality of life instru-
ments, we have studied GERD patients more comprehen-
sively than previous studies [31,32,35]; however, our
results are confined to GERD patients with moderate to
severe symptoms who were participating in a clinical
study. In addition, our comparison with population data
is based on historical data. Despite the impressive respon-
sive of the QOLRAD scores to esomeprazole treatment,
one has to keep in mind that this study was not a rand-
omized controlled trial. In regards to evaluation of valid-
ity, another limitation of our study is that we did not
generate a priori predictions regarding correlations
between the utility instruments and other measures. Had
we generated such a priori predictions our conclusion
about the validity of the instruments might be stronger.
Data on utility measures in GERD patients are sparse. We
observed important disutility measured with the FT, SG,
and HUI 3. The results suggest that the FT and HUI 3 are
valid tools for the assessment of HRQL in patients with
GERD. We were specifically interested in exploring the rel-
ative validity of utility instruments in patients with GERD.
In general, the correlations with other HRQL instruments
were moderate. In contrast, the SG showed poor construct
validity. Moreover, the FT shows better correlation with
the four symptoms questionnaire than the SG and the
HUI 3. Thus, our findings suggest that the FT and the HUI
3 are more appropriate indicators of HRQL impairment
than the SG in these patients. Studies that use the FT, SG,
HUI and SF-36 simultaneously are rare. We have previ-
ously observed a similar pattern of correlations in patients
with chronic obstructive pulmonary disease (COPD) [24].
The correlations of the FT and HUI 3 with the SF-36 were
higher compared to those of the SG with the SF-36. Thus,
there is external evidence that the FT and HUI 3 show
greater validity for the assessment of HRQL than the SG.
The data also indicate that the disutility in patients with
moderate to severe GERD is similar to that of moderate to
severe COPD [24]. The utility scores obtained with the SG
are lower than what was previously reported for SG scores
in patients with asthma [38] and comparable to those of
minor stroke survivors [39].
We also found reductions in the SF-36 scores on all 8
domains in GERD patients. Compared to the Canadian
and US general population, patients in this study had sig-
nificantly reduced scores in the SF-36 MCS and PCS [33-
36]. The SF-36 PCS scores are comparable to patients with
clinical depression and hypertension. On the other hand,
GERD patients have significantly worse SF-36 MCS scores
than patients with diabetes mellitus and depression.
The QOLRAD results suggest that GERD has the greatest
impact on the vitality and food/drink domains. These
results are similar to those reported by Wiklund et al. [31]
confirming the negative impact of GERD on the daily
functioning of affected patients.
Health administrators and payers are interested in the
magnitude of work productivity loss due to GERD [41].
Wahlqvist et al. showed that patients with GERD symp-
toms report 23% reduced productivity while at work, and
30% reduced productivity while doing regular daily activ-
ities in a Swedish population [32]. Our study supports the
finding of impaired productivity in patients with moder-
ate to severe GERD, but the estimates of work loss are
somewhat lower demonstrating that about 16% of the
work time is lost due to the illness. Since GERD affects
approximately 9% of the Canadian population [5],
impaired productivity has important economic conse-
quences on society if it is not treated effectively.
Table 7: Baseline mean (standard deviation) SF-36 physical component summary (PCS) and mental component summary (MCS) 
scores for patients with gastroesophageal reflux disease compared with data reported by Revicki et al. [35] and Hopman et al. [33]
SF-36 scale GERD (this study) Canadian 
population§ 
(N = 9,423)
US Population† 
(N = 2,474)
Clinical 
depression† 
(N = 502)
Diabetes† 
(N = 541)
Hypertension† 
(N = 2,089)
PCS 45.1 (n = 212) (8.7) 51.4* (8.5) 50.0* (10.0) 45.0 (12.1) 41.5* (11.3) 44.3 (10.8)
MCS 47.6 (n = 212) (11.0) 52.6* (8.5) 50.0* (10.0) 34.8* (12.2) 51.9* (9.6) 52.2* (9.3)
*P < 0.001 compared to our GERD patients.
§ Data from Hopman et al.
† Data from Revicki et al.BMC Gastroenterology 2005, 5:23 http://www.biomedcentral.com/1471-230X/5/23
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Conclusion
In summary, we found that GERD has significant impact
on utilities scores, HRQL and work productivity in
patients with moderate to severe illness. The impact of the
disease is similar in magnitude to other chronic condi-
tions that are less responsive to treatment. In addition,
utility instruments such as the FT and HUI 3 provide valid
measurements of the impact of GERD on HRQL.
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